Cyteir Therapeutics Inc chart

Last update: 2022-12-30
Key statistics and financials
Revenue per share N/A
Dividend & YieldN/A$ (N/A)
Beta N/A
Market capitalization 62.02M
Operating cash flow -45.23M
ESG Scores unknown

Company description

Cyteir Therapeutics, Inc., a clinical-stage biotechnology company, develops and commercializes the next-generation of precision oncology medicines. Its lead product CYT-0851, a novel, oral, once-daily, small molecule drug candidate that is in Phase I/II clinical trial for monotherapy in solid tumors and hematologic malignancies, as well as for combination therapy in solid tumors and hematologic malignancies. The company is also developing CYT-1853, which is in preclinical trials for solid tumors and hematologic malignancies. The company was incorporated in 2012 and is based in Lexington, Massachusetts.

Sector: Healthcare - Industry: Biotechnology

Financial data

Financial Statements

Cashflow Statement 2019-12-31 2020-12-31 2021-12-31
Change To Liabilities -884k 1.03M 38k
Total Cashflows From Investing Activities -133k -850k -1.19M
Net Borrowings
Total Cash From Financing Activities 36.89M 1.43M 216.01M
Change To Operating Activities -1.28M 439k 2.11M
Issuance Of Stock 268k 1.43M 136.35M
Net Income -15.04M -20.82M -42.13M
Change In Cash 19.2M -17.96M 178.78M
Effect Of Exchange Rate
Total Cash From Operating Activities -17.56M -18.54M -36.03M
Depreciation 215k 351k 479k
Change To Account Receivables
Other Cashflows From Financing Activities -1.08M
Change To Netincome -568k 467k 3.46M
Capital Expenditures -133k -850k -1.19M

Income Statement 2019-12-31 2020-12-31 2021-12-31
Research Development 79k 16.77M 30.96M
Income Before Tax -15.04M -20.82M -42.13M
Net Income -15.04M -20.82M -42.13M
Selling General Administrative 3.35M 4.18M 11.3M
Gross Profit -12.68M
Ebit -16.11M -20.94M -42.26M
Operating Income -16.11M -20.94M -42.26M
Interest Expense
Income Tax Expense
Total Revenue 8k
Cost Of Revenue 12.69M
Total Other Income ExpenseNet 1.06M 120k 133k
Net Income From Continuing Ops -15.04M -20.82M -42.13M
Net Income Applicable To Common Shares -15.04M -20.82M -42.13M

Balance Sheet Statement 2019-12-31 2020-12-31 2021-12-31
Total Liabilities 2.29M 4.36M 8.1M
Total Stockholder Equity -28.34M -48.03M 187.29M
Other Current Liabilities
Total Assets 31.37M 13.73M 195.39M
Common Stock 5k 2k 35k
Other Current Assets 1.1M 871k 1.55M
Retained Earnings -29.1M -49.93M -92.05M
Treasury Stock
Cash 29.01M 10.94M 189.72M
Total Current Liabilities 1.97M 3.14M 7.51M
Other Stockholder Equity
Property, Plant, and Equipment 788k 1.29M 2.06M
Total Current Assets 30.44M 12.13M 193.08M
Net Tangible Assets -28.34M -48.03M 187.29M
Net Receivables 164k 63k 38k
Accounts Payable 602k 1.69M 1.78M


Insider Transactions

Here are the insider transactions of stock shares related to Cyteir Therapeutics Inc:

Filer Name Transaction Text Ownership Date Filer Relation Shares
RENSCHLER MARKUS FStock Award(Grant) at price 1.49 per share.D2023-01-13Chief Executive Officer5k
GAIERO DAVID GStock Award(Grant) at price 1.49 per share.D2023-01-13Chief Financial Officer5k
RENSCHLER MARKUS FConversion of Exercise of derivative security at price 1.03 - 1.20 per share.D2022-12-21Chief Executive Officer136.78k
ZAKRZEWSKI JOSEPH SPurchase at price 1.30 per share.D2022-12-07Director21.2k
NOVO HOLDINGS A/SSale at price 4.01 per share.D2022-07-20Beneficial Owner of more than 10% of a Class of Security900k
ZAKRZEWSKI JOSEPH SPurchase at price 1.61 per share.D2022-05-12Director743
ZAKRZEWSKI JOSEPH SPurchase at price 1.70 - 1.89 per share.D2022-05-11Director50.41k
THERO JOHN FPurchase at price 2.00 per share.D2022-05-10Director10k
ZAKRZEWSKI JOSEPH SPurchase at price 9.85 - 10.18 per share.D2021-12-28Director1.1k
GAIERO DAVID GConversion of Exercise of derivative security at price 1.68 per share.D2021-12-20Chief Financial Officer4.1k
ZAKRZEWSKI JOSEPH SPurchase at price 9.88 per share.D2021-12-17Director200
ZAKRZEWSKI JOSEPH SPurchase at price 10.47 - 11.12 per share.D2021-12-15Director3.7k
GEORGE JEAN MI2021-06-22Director2.44M
NOVO HOLDINGS A/SPurchase at price 18.00 per share.D2021-06-22Beneficial Owner of more than 10% of a Class of Security277.78k
NOVO HOLDINGS A/SD2021-06-22Beneficial Owner of more than 10% of a Class of Security4.56M
ZAKRZEWSKI JOSEPH SI2021-06-22Director58.67k
VENROCK ASSOCIATES VII, L.P.I2021-06-22Beneficial Owner of more than 10% of a Class of Security3.26M
NOVO A/SPurchase at price 18.00 per share.D2021-06-22Beneficial Owner of more than 10% of a Class of Security277.78k
NOVO A/SD2021-06-22Beneficial Owner of more than 10% of a Class of Security4.56M
NAESENS JANWILLEMPurchase at price 18.00 per share.I2021-06-22Director277.78k
NAESENS JANWILLEMI2021-06-22Director3.26M
DROIA INVEST II SCSPPurchase at price 18.00 per share.I2021-06-22Beneficial Owner of more than 10% of a Class of Security277.78k
DROIA INVEST II SCSPI2021-06-22Beneficial Owner of more than 10% of a Class of Security3.26M
GEORGE JEAN MBAI2021-06-22Director2.44M
ROMBERGER TIMOTHYD2021-06-22Director79.06k

Insider transaction explanations

Insider buying is the legal purchase of shares by a senior executive or director of a company. "Filer Name" corresponds to the name of the stock buyer or seller. "Transaction Text" describes the transaction. "Ownership" gives information about the transaction type. "Date" is the reported transaction date. "Filer Relation" gives the role of the insider in the company. "Shares" is the value of the transaction. You will find the complete description of the General Transaction Codes on the SEC dedicated page


Investment strategy backtesting

These are the result of three automatic investment systems applied to Cyteir Therapeutics Inc. You will find the performance of an systematic investment system, a momentum strategy, and a buy the dip trading strategy.


Systematic investment results on Cyteir Therapeutics Inc

Here is the result of two systematic investment strategies applied to Cyteir Therapeutics Inc. The first strategy automatically buys the first day of the month, and the second strategy buys the fifteenth day of the month.

Systematic investment equity curve on Cyteir Therapeutics Inc

The following chart shows the equity curve of the two systematic investment strategies applied to Cyteir Therapeutics Inc:

Cyteir Therapeutics Inc automated entries

The systematic investment strategy that buys the first day of the month would give a performance of -77.05% on the backtest period.

Performance at glance

Performance

-77.05 %

Latent gain

-1296.25 $

Invested capital

1682.25 $

Annualized return

-18.61 %
Build your Trading System
Automated Trading using Prorealtime ebook

Momentum strategy results on Cyteir Therapeutics Inc

This is the result of two momentum investment strategies applied to Cyteir Therapeutics Inc. The first strategy uses a momentum signal calculated on one quarter, and the second uses a momentum signal calculated on two quarters.

Momentum entry openings on Cyteir Therapeutics Inc

The following chart shows all the entries opened by the momentum investment system on Cyteir Therapeutics Inc:

Cyteir Therapeutics Inc momentum entries
  • The first momentum investment strategy would give -73.1% of return on Cyteir Therapeutics Inc. That represents -3649.44$ of latent gain with 4992.72$ of employed capital.
  • The second momentum investment strategy would give -78.43% of return on Cyteir Therapeutics Inc. That represents -2358.36$ of latent gain with 3006.84$ of employed capital.
Performance at glance (1Q Momentum)

Performance

-73.1 %

Latent gain

-3649.44 $

Invested capital

4992.72 $

Annualized return

-32.71 %
Performance at glance (2Q Momentum)

Performance

-78.43 %

Latent gain

-2358.36 $

Invested capital

3006.84 $

Annualized return

-21.43 %

Momentum equity curve on Cyteir Therapeutics Inc

The following chart shows the equity curve of the two momentum strategies applied to Cyteir Therapeutics Inc:

Cyteir Therapeutics Inc momentum equity

Note: the dividends potentially given by Cyteir Therapeutics Inc are not integrated into the calculation of the equity curve neither the performance of the strategy. The integration of the dividends will be available soon.


Employed capital on Cyteir Therapeutics Inc

The following chart shows the employed capital evolution of the two momentum strategies on Cyteir Therapeutics Inc since the beginning:

Cyteir Therapeutics Inc

Note: the algorithm buys for a maximum of 250$ per entry. If the stock price is greater than 250$, the system buys only one stock per entry. The investment system stops automatically when the financial exposure reaches 10000$.


Buy the dip strategy result on Cyteir Therapeutics Inc

Buy the dip entry openings on Cyteir Therapeutics Inc

Cyteir Therapeutics Inc

The performance achieved by the robo-advisor on Cyteir Therapeutics Inc is -69.99%. That represents -180.05$ of latent gain with 257.25$ of employed capital. The following chart shows Cyteir Therapeutics Inc stock price with all the entries opened by the automated investment system.

Note: The blue line represents the weekly stock price of Cyteir Therapeutics Inc, and the green triangles represent the entry openings. The artificall robo-advisor needs at least 100 weeks of trading history to work.

Performance at glance

Performance

-69.99 %

Latent gain

-180.05 $

Invested capital

257.25 $

Annualized return

-32.71 %

Equity curve of the strategy applied to Cyteir Therapeutics Inc

The following chart shows the result of the investment strategy applied to Cyteir Therapeutics Inc:

Cyteir Therapeutics Inc

Note: the dividends potentially given by Cyteir Therapeutics Inc are not integrated into the calculation of the equity curve neither the performance of the strategy. The integration of the dividends will be available soon.


Employed capital on Cyteir Therapeutics Inc

The following chart shows the employed capital evolution since the beginning of the investment strategy on Cyteir Therapeutics Inc:

Cyteir Therapeutics Inc

Note: the algorithm buys for a maximum of 250$ per entry. If the stock price is greater than 250$, the system buys only one stock per entry. The investment system stops automatically when the financial exposure reaches 10000$.


Investment strategies comparison on Cyteir Therapeutics Inc

In this section, I will compare the three previous investment strategies applied to Cyteir Therapeutics Inc.

Equity curve comparison on Cyteir Therapeutics Inc

The following chart shows the equity curve of the artificall advisor, the trend folowing and the automatic investment strategies:

Cyteir Therapeutics Inc investment strategy comparison

Employed capital comparison on Cyteir Therapeutics Inc

Cyteir Therapeutics Inc investment comparison

Performance comparison on Cyteir Therapeutics Inc

Strategy Latent Profit Growth Employed capital CAGR
Automatic investment -77.05% -1296.25$ 1682.25$ -18.61%
Momentum 1 quarter -73.1% -3649.44$ 4992.72$ -18.74%
Momentum 2 quarters -78.43% -2358.36$ 3006.84$ -21.43%
Non-directional -69.99% -180.05$ 257.25$ -32.71%
Annualized return comparison

Automatic investment

-18.61 %

Momentum 1Q

-21.43 %

Momentum 2Q

-21.43 %

Non-directional

-32.71 %

Correlated stocks

Here are the most positively and negatively correlated stocks with Cyteir Therapeutics Inc:

Positive correlations

Most correlated stocks this year

  • Cyteir Therapeutics Inc

  • Most correlated stocks last 3 months

  • ORIENTAL PRESS
  • Cyteir Therapeutics Inc
  • LAI SUN INTL

  • Negative correlation

    Most negatively correlated stocks this year


    Most negatively correlated stocks last 3 months


    Note: The algorithm computes the probability of correlation between Cyteir Therapeutics Inc and the other stocks. There may be false positives or some missing correlated stocks. If the price of Cyteir Therapeutics Inc does not vary for 36 weeks, the correlation calculation result will be wrong.


    Company information

    Company name Cyteir Therapeutics Inc
    Country United States
    City Lexington
    Address 128 Spring Street
    Phone 857 285 4140
    Website cyteir.com
    FullTime employees 40
    Industry Biotechnology
    Sector Healthcare
    Exchange XNYS
    Ticker CYT
    Market www.nyse.com

    Cyteir Therapeutics Inc ESG Scores

    Environment scores

    Environment ESG Factors Scores
    Environment Score 0
    Peer Environment Performance unknown
    Environment Percentile unknown
    Palm Oil unknown
    Nuclear unknown
    Fur Leather unknown
    GMO unknown
    Coal unknown
    Pesticides unknown
    Animal Testing unknown

    Social scores

    Social ESG Factors Scores
    Social Score 0
    Peer Social Performance unknown
    Social Percentile unknown
    Highest Controversy unknown
    Peer Highest Controversy Performance unknown
    Adult unknown
    Gambling unknown
    Alcoholic unknown
    Tobacco unknown
    Catholic unknown
    Controversial Weapons unknown
    Small Arms unknown
    Military Contract unknown
    Peer Count unknown

    Related Controversy:


    Governance scores

    Governance ESG Factors Scores
    Governance Score 0
    Peer Governance Performance unknown
    Governance Percentile unknown

    ESG at glance
    Total ESG Scores: unknown
    Environment Score: 0
    Social Score: 0
    Governance Score: 0

    ESG Performance: unknown

    Peer Group: unknown

    Peer Esg Score Performance: unknown

    Rating Year: unknown

    Rating Month: unknown

    Max Age: unknown

    Percentile: unknown